This contract expires in 103 days (Jan 31, 2027).
GOLDBELT FRONTIER, LLC - CONFERENCE LOGISTICS SUPPORT - HPSB - LOGISTICS SUPPORT SERVICE INCLUDES ACTING AS THE PRIMARY LIAISON BETWEEN HPSB STAFF AND EVENT VENUE.
Key Details
Description
CONFERENCE LOGISTICS SUPPORT - HPSB - LOGISTICS SUPPORT SERVICE INCLUDES ACTING AS THE PRIMARY LIAISON BETWEEN HPSB STAFF AND EVENT VENUE.
Context & Analysis
On Jan 21, 2026, Department of Health and Human Services obligated $601,948.32 to GOLDBELT FRONTIER, LLC for conference logistics support - hpsb - logistics support service includes acting as the primary liaison between hpsb staff and event venue.. The award is classified under NAICS 541714 — RESEARCH AND DEVELOPMENT IN BIOTECHNOLOGY (EXCEPT NANOBIOTECHNOLOGY) and issued as a firm fixed price contract. Competition extent: full and open competition with 1 offer received. Performance is located in ALEXANDRIA, VA. The contract is scheduled through Jan 31, 2027 — approximately 3 months remaining. This award is one of several similar procurements from Department of Health and Human Services under NAICS 541714 — related awards are listed below.
Contractor Information
Related Opportunities
Biomedical Advanced Research and Development Authority (BARDA) Broad Agency Announcement (BAA)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
BARDA DRIVe EZ-BAA (EZBAA - 22-100-SOL-00003)
HEALTH AND HUMAN SERVICES, DEPARTMENT OF.OFFICE OF ASSISTANT SECRETARY FOR PREPAREDNESS AND RESPONSE.BARDA - ASPR / DAAPPO / BARDA DCMA
Similar Awards
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ALLUCENT GOVERNMENT SERVICES (US) LLC
$370.1M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
ICON GOVERNMENT AND PUBLIC HEALTH SOLUTIONS, INC.
$330.2M
CLINICAL SERVICES NETWORK- CLINICAL TRIAL PLANNING AND EXECUTION
TECHNICAL RESOURCES INTERNATIONAL, INC.
$317.1M
ANTIBIOTIC FOR TREATMENT OF A BIOTHREAT INDICATION
PARATEK PHARMACEUTICALS, INC
$265.3M
ASPR-18-04963 -- FUNDING FOR BALOXAVIR MARBOXIL ACTIVITIES FOR BASE PERIOD TASK UNDER THE GENENTECH OTA
GENENTECH INC
$243.7M
Stay Updated
Get notified about new opportunities matching your interests.